© Reuters. FILE PHOTO: An indication stands outdoors a Abbvie facility in Cambridge, Massachusetts, U.S., Might 20, 2021. REUTERS/Brian Snyder/File Picture (Reuters) – AbbVie (NYSE:) mentioned on Wednesday it could purchase Cerevel Therapeutics, a developer of medication for neurological situations, for about $8.7 billion in a bid to exchange income as its arthritis drug Humira…
© Reuters. FILE PHOTO: Take a look at tubes are seen in entrance of a displayed Abbvie brand on this illustration taken, Could 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photograph By Saqib Iqbal Ahmed NEW YORK (Reuters) – Buying and selling within the choices of Cerevel Therapeutics Holdings Inc skilled an uncommon surge together with its inventory…
© Reuters AbbVie (ABBV) enters settlement to accumulate Cerevel Therapeutics (CERE) AbbVie Inc . (NYSE:) introduced Wednesday, alongside Cerevel Therapeutics Holdings Inc (NASDAQ:), that the 2 have entered right into a definitive settlement for AbbVie to accumulate Cerevel, in addition to its strong neuroscience pipeline of a number of clinical-stage and preclinical candidates. The acquisition…
© Reuters Immunogen (IMGN) shares surge on information of takeover by AbbVie (ABBV) AbbVie (NYSE:) introduced Thursday that it’s going to purchase Immunogen (IMGN) and its flagship most cancers remedy, Elahere, in a deal value $31.26 per share. The transaction values ImmunoGen (NASDAQ:) at a complete fairness worth of roughly $10.1 billion and is anticipated…
